Evidence map›Paper›PMID 30007894›Full record

Trial reportEuropean journal of cancer (Oxford, England : 1990)2018

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

Ting Bao, Andrew D Seidman, Lauren Piulson, Emily Vertosick, Xi Chen, Andrew J Vickers, Victoria S Blinder, Wanqing I Zhi, Qing Li, Linda T Vahdat and 3 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of cancer (Oxford, England : 1990), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04461977 (Acupuncture for Treatment of Peripheral Neuropathy Induced by Neoadjuvant or Adjuvant Paclitaxel in Early Stage Breast Cancer), which is not on this map. Cited by 59 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 6 pooled it
3.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04461977 nacompletednot on this mapstarted 2020, after this paper: background citation

Acupuncture for Treatment of Peripheral Neuropathy Induced by Neoadjuvant or Adjuvant Paclitaxel in Early Stage Breast Cancer: a Sham Controlled, Randomized Study

TypeinterventionalSponsorInstituto Brasileiro de Controle do CancerRan2020 to 2024Enrolled60ConditionsPeripheral Neuropathy Due to ChemotherapyArmsTrue acupuncture, Sham acupuncture
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 6 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ting BaoMemorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. Electronic address: baot@mskcc.org.
Andrew D SeidmanMemorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: seidmana@mskcc.org.
Lauren PiulsonMemorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. Electronic address: piulsonl@mskcc.org.
Emily VertosickMemorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA. Electronic address: vertosie@mskcc.org.
Xi ChenMemorial Sloan Kettering Cancer Center, 444 E 68th Street, New York, NY, 10065, USA. Electronic address: chenx2@mskcc.org.
Andrew J VickersMemorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA. Electronic address: vickersa@mskcc.org.
Victoria S BlinderMemorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York, NY, 10017, USA. Electronic address: blinderv@mskcc.org.
Wanqing I ZhiMemorial Sloan Kettering Cancer Center Commack, 650 Commack Road, Commack, NY, 11725, USA. Electronic address: zhiw@mskcc.org.
Qing LiMemorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. Electronic address: liq2@mskcc.org.
Linda T VahdatMemorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: vahdatl@mskcc.org.
Maura N DicklerMemorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: dicklerm@mskcc.org.
Mark E RobsonMemorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: robsonm@mskcc.org.
Jun J MaoMemorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. Electronic address: maoj@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Estrogen Deprivation and Aromatase Inhibitor associated ArthralgiaR01CA158243 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAO, JUN J · 2011 to 2015
$2.2M
Acupuncture to Prevent Chemotherapy Dose ReductionR21CA173263 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI BAO, TING · 2013 to 2014
$349k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA158243NCI NIH HHS R21 CA173263
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side-effect of neurotoxic chemotherapy for cancer patients. We evaluated the preliminary efficacy of acupuncture in preventing worsening CIPN in patients receiving paclitaxel.

methodsIn this phase IIA single-arm clinical trial, we screened stage I-III breast cancer patients receiving neoadjuvant/adjuvant weekly paclitaxel for development of CIPN. The primary objective was to assess acupuncture's efficacy in preventing the escalation of National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0, grade II CIPN to higher grades. Acupuncture was deemed worthy of further study if 23 or more of the 27 enrolled patients did not develop grade III CIPN. Outcome measures (NCI-CTCAE CIPN grade, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-Ntx], Neuropathic Pain Scale [NPS]) were obtained weekly during the intervention.

resultsOf 104 patients screened, 37 developed grade II CIPN (36%), and 28 (27%) enrolled into the intervention phase; one was removed due to protocol violation. Of the 27 patients receiving acupuncture, 26 completed paclitaxel treatment without developing grade III CIPN, meeting our prespecified success criteria for declaring acupuncture worthy of further study. FACT/GOG-Ntx and NPS scores remained stable during the intervention while continuing weekly paclitaxel. Acupuncture treatment was well tolerated; 4 of 27 (15%) patients reported grade I bruising.

conclusionsAcupuncture was safe and showed preliminary evidence of effectiveness in reducing the incidence of high grade CIPN during chemotherapy. A follow-up randomised controlled trial is needed to establish definitive efficacy in CIPN prevention for patients at risk.

Indexed as

Acupuncture TherapyAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantContusionsFemaleHumansMiddle AgedNeoadjuvant TherapyPaclitaxelPeripheral Nervous System DiseasesSeverity of Illness IndexTreatment OutcomePaclitaxelAcupunctureBreast cancerChemotherapyChemotherapy-induced peripheral neuropathyCIPNPaclitaxel

Identifiers

PMID30007894
PMCPMC6147260
OpenAlexW2884637184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.